Clinical Trials Logo

Drug Resistant Epilepsy clinical trials

View clinical trials related to Drug Resistant Epilepsy.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06436547 Not yet recruiting - Clinical trials for Epilepsy, Drug Resistant

Subiculum Electrical Stimulation for Temporal Lobe Epilepsy With Biliteral Hippocampus Sclerosis(SESTB)

Start date: May 30, 2024
Phase: N/A
Study type: Interventional

The primary objective of this research is to study the efficacy and safety of deep brain stimulation (DBS) of Subiculum as adjunctive therapy for reducing the frequency of seizures in drug-resistant temporal lobe epilepsy with bilateral hippocampal sclerosis

NCT ID: NCT06425029 Not yet recruiting - Epilepsy Clinical Trials

Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application

SONATA
Start date: July 1, 2024
Phase: N/A
Study type: Interventional

This is a prospective, placebo-controlled, double-blinded randomized study of self-administered auditory intervention in a naturalistic home environment.

NCT ID: NCT06388707 Not yet recruiting - Epilepsy Clinical Trials

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

Start date: August 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This will be a prospective, open-label, single-arm, multi-center, pilot study to evaluate the safety, tolerability, and preliminary efficacy of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in patients with drug-resistant unilateral or bilateral temporal lobe epilepsy (DR-TLE).

NCT ID: NCT06387186 Not yet recruiting - Refractory Epilepsy Clinical Trials

Leucine Enriched Essential Amino Acid Powder as an Add-on to a Classic Ketogenic Diet in Refractory Epilepsy

Start date: April 2024
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety and tolerability of a Leucine-Enriched Essential Amino Acid (LEAA) Powder as an add-on to a classic ketogenic diet (KD) in pediatric and adult patients with refractory epilepsy.

NCT ID: NCT06366009 Not yet recruiting - Epilepsy Clinical Trials

Assessment of Patients With Drug-resistant Temporal Lobe Epilepsy With EEG Extended With Intra-auricular Electrodes

Start date: April 8, 2024
Phase:
Study type: Observational

The study aims to evaluate the effectiveness of long-term video EEG monitoring using 10-20 electrodes extended with intra-auricular electrodes in locating the seizure onset zone and interictal epileptiform discharges (IEDs) in patients with temporal lobe epilepsy (TLE) and nontemporal lobe epilepsy (non-TLE).

NCT ID: NCT06364085 Not yet recruiting - Clinical trials for Epilepsy, Drug Resistant

Enhancing Epilepsy Management With Precision Deep Brain Stimulation

EPI-BOOST
Start date: June 2024
Phase: N/A
Study type: Interventional

The goal of this study is to evaluate the effectiveness of objective neural response feedback on deep brain stimulation (DBS) programming for drug-resistant epilepsy in a prospective observational cohort study.

NCT ID: NCT06340802 Not yet recruiting - Clinical trials for Drug Resistant Epilepsy

A First in hUman Study for Resistant Epilepsy With the Vagus Nerve stimulatiOn Device by syneRgia medicAl

AURORA
Start date: June 2024
Phase: N/A
Study type: Interventional

This is an open label, single arm, interventional, prospective first in human study, designed to evaluate the safety of the NAO.VNS SYSTEM.

NCT ID: NCT06334952 Not yet recruiting - Epilepsy Clinical Trials

Efficacy of Personnalized Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epileptic

GALVANI GS-3
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to to obtain a significant decrease in seizure frequency in patients with refractory focal epilepsy after applying treatment of cathodal tDCS, compared to sham stimulation drug-resistant epileptic patient. The main questions it aims to answer are: - Changes in quality of life - Percent of newly reported side effects after the stimulation period - Scores in epilepsy severity. Participants will be randomized in a cross-over, and will receive 10 days of tDCS or Sham. Each day will allow 2 periods of 20 minutes stimulation separated by 20 minutes off (with 40 minutes of cathodal stimulation total).

NCT ID: NCT05555537 Not yet recruiting - Clinical trials for Drug Resistant Epilepsy

MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy

Start date: November 1, 2022
Phase:
Study type: Observational

Evaluation of the role of estimation of serum level of miRNAs223 and HMGB1in detection of patient with drug resistant epilepsy. Early detection of the prognosis might help in guiding patients for proper management and treatment strategy. This may open the door for new drug trials.

NCT ID: NCT05527093 Not yet recruiting - Epilepsy Clinical Trials

Cartography of Social Cognition Network and Their Alterations in Patients With Epilepsy

SocrAlt
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

Social cognition, which refers to the ability to interpret social information and behave accordingly in a social environment, is crucial in everyday life. But this ability has been shown to be altered in patients with epilepsy, especially in medial temporal lobe epilepsy, which leads to a deterioration in the patient's quality of life. However, the mechanisms of those deficiencies remain largely unknown. The Team objective is to achieve a structural and functional cartography of the social cognition network in 20 healthy subjects and 20 patients with drug-resistant medial temporal lobe epilepsy (before and one year after resective surgery of the epileptogenic focus). Social cognition deficiencies will be assessed using a specifically dedicated neuropsychological assessment validated in French (Batteries de Cognition Sociale BCS). Brain structural analyses will be performed on a 3-Tesla MRI (3T MRI), including an anatomical T1 sequence, a High Angular Resolution Diffusion Imaging (HARDI) to assess the morphology and macrostructural characteristics of long and short white matter tracts involved in social cognition, and quantitative MRI and Hybrid Diffusion Imaging (HYDI) to assess their microstructure. Functional connectivity will be assessed using an ultra-high-field 7-Tesla MRI (7T MRI), with acquisition in resting state and during specific social cognition tasks. Joint analysis of structural and functional connectivity will enable the team to assess the alterations of social cognition networks in patients with epilepsy and their reorganisations after epilepsy surgery.